← Back to headlines
Stock Market: The risk of the... weekend that investors fear
CervoMed (CRVO)'s fourth-quarter results highlight significant advancements in its Neflamapimod program, targeting Dementia Lewy Bodies (DLB).
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
